In an effort to change the way bleeding has been treated in the operating room and on the battlefield, Battelle http://battelle.org involved in research and commercialization, has announced a partnership with the Feinstein Institute for Medical Research, http://feinsteininstitute.org the research arm of the North Shore-LIJ Health System.
Studies conducted during the past ten years, by the Feinstein Institute indicate that a nerve stimulation device can significantly reduce bleeding. Electrical stimulation of neural pathways to the spleen for as little as 60 seconds can prepares the body for clotting in the event of a wound. The primed coagulation system is able to clot 50 percent more rapidly and reduce the volume of blood loss by 50 percent.
Battelle’s strategic partnership with the Feinstein Institute comes at a time of continuing growth in the $4.5 billion market for neurostimulation devices. This market is expected to grow to over $7.8 billion by 2018, according to MicroMarketMonitor, a market research firm.
The two organization will work together to create a “Neural Tourniquet, a technology to help staunch blood loss through electronic nerve stimulation. The device with applications to surgery, emergency medicine, and to help on the battlefields, is slated to enter the market in the next three to five years.
The Neural Tourniquet is one of the latest advancement in bioelectronics medicine which is a rapidly developing field combining molecular medicine, bioengineering, and neuroscience to discover and develop nerve stimulating and sensing technologies to regulate biological processes.